STOCK MARKET BSE NSE

Cipla reports Q4 net profit at Rs 179 crore

Revenue rose by 3 per cent at Rs 3,698 crore during the quarter, against Rs 3,582 crore in the same period last year, the company statement said in a release.

Published: 22nd May 2018 08:00 PM  |   Last Updated: 22nd May 2018 08:35 PM   |  A+A-

An employee works at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015. | Reuters

By PTI

MUMBAI: Pharma major Cipla today reported a net profit of Rs 179 crore for the quarter ended March on improved sales in the domestic market and South Africa.

The drugmaker had posted a net loss of Rs 62 crore in the same quarter last year.

Revenue rose by 3 per cent at Rs 3,698 crore during the quarter, against Rs 3,582 crore in the same period last year, the company statement said in a release.

The firm said it witnessed a strong momentum across key markets with India business delivering a strong quarter with growth at 21 per cent (GST adjusted) year-on-year basis.

Among overseas markets, South Africa, API, Europe and Sub-Saharan markets also continued strong momentum, it added.

The US business saw launches of key products and focused effort was made towards building a strong specialty portfolio for the US market, the release said.

The company increased its R&D investments in the quarter to 7.6 per cent of revenues, driven by clinical trial charges related to Advair among others, it added.

It reported full year revenues of Rs 15,219 crore, growing by 4 per cent year on year.

The EBITDA, before exceptional items, grew by 14.2 per cent at Rs 2,826 crore and the net profit increased by 40 per cent at Rs 1,411 crore in financial year 2017-18.

Cipla managing director and global chief executive officer Umang Vohra said during FY18, the firm's focus remained on strengthening portfolio and deepening presence in priority markets.

"Our focus for next year will be to continue our growth trajectory in key markets and investments in portfolio for sustainable growth," he said.

The company's scrip ended 0.88 per cent higher at Rs 524.35 on the BSE today, against 0.10 per cent rise in the benchmark.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp